STAY INFORMED. VISIT NHIA.ORG/COVID19 FOR INFORMATION AND RESOURCES ABOUT CORONAVIRUS DISEASE (COVID-19).

INFUSION News

Considerations for Addressing ExactaMix Automated Compounding Device (ACD) Valve Set Supply Disruption

On April 19, 2022, Baxter announced a supply disruption of the ExactaMix valve sets (ExactaMix 1200 Valve Set H938792 and ExactaMix 2400 Valve Set H938724) due to raw material constraints that are impacting production volumes. As a result, healthcare providers and institutions are driven to consider conservation measures when compounding using the ExactaMix Automated Compounder.

The nature of this supply disruption is of grave concern, limiting the ability to safely prepare parenteral nutrition and other intravenous sterile products compounded using the ExactaMix device. Typical strategies for conservation may not easily translate to this supply disruption. NHIA has collaborated with the the American Society for Parenteral and Enteral Nutrition (ASPEN), the American Society for Health System Pharmacists (ASHP) and the Institute for Safe Medication Practices (ISMP) to provide considerations for potential approaches to managing this supply disruption.

Download the considerations document (pdf)

Important Notes:

  • The recommendations do not constitute medical or professional advice and should not be taken as such. To the extent the information published herein may be used to assist in the care of patients, this is the result of the sole professional judgment of the attending health professional whose judgment is the primary component of quality medical care. The information presented herein is not a substitute for the exercise of such judgment by the health professional and healthcare institution.
  • No single strategy will work for all organizations and are less than ideal for providing safe and optimal patient care. Institutions must carefully consider options and weigh the risks and benefits prior to implementation.
  • The use of the valve sets outside of the Operator Manual by extending the use of the valve sets for longer than 24 hours or to deliver more than 150 liters of fluid, whichever comes first, has not been validated and is not recommended by Baxter.
  • Baxter is not aware of any other valve set that is compatible with, works with, or has been validated with the ExactaMix Automated Compounding Device.

 

Download the considerations document (pdf)

NHIA Logo

Related Posts

NHIA Releases Comments on California Senate Bill 958

NHIA submitted comments on California SB 958, the Medication and Patient Safety Act of 2022, supporting amendments to the proposed legislation that allow for infused medications to be administered in the enrollee’s home when the physician and patient determine it is in the patient’s best interest and weighing in on various other aspects of the bill.

Read More »